Last reviewed · How we verify

panitumumab, mytomicin C, 5-FU, radiation

Grupo Espanol Multidisciplinario del Cancer Digestivo · Phase 2 active Small molecule

panitumumab, mytomicin C, 5-FU, radiation is a Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo. It is currently in Phase 2 development. Also known as: Vectibix.

At a glance

Generic namepanitumumab, mytomicin C, 5-FU, radiation
Also known asVectibix
SponsorGrupo Espanol Multidisciplinario del Cancer Digestivo
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about panitumumab, mytomicin C, 5-FU, radiation

What is panitumumab, mytomicin C, 5-FU, radiation?

panitumumab, mytomicin C, 5-FU, radiation is a Small molecule drug developed by Grupo Espanol Multidisciplinario del Cancer Digestivo.

Who makes panitumumab, mytomicin C, 5-FU, radiation?

panitumumab, mytomicin C, 5-FU, radiation is developed by Grupo Espanol Multidisciplinario del Cancer Digestivo (see full Grupo Espanol Multidisciplinario del Cancer Digestivo pipeline at /company/grupo-espanol-multidisciplinario-del-cancer-digestivo).

Is panitumumab, mytomicin C, 5-FU, radiation also known as anything else?

panitumumab, mytomicin C, 5-FU, radiation is also known as Vectibix.

What development phase is panitumumab, mytomicin C, 5-FU, radiation in?

panitumumab, mytomicin C, 5-FU, radiation is in Phase 2.

Related